Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 <scp>ALLG MM23</scp> ( <scp>SeaLAND</scp> ) trial

Matthew J. Rees, Masa Lasica, Anna Kalff, Michael Low, Rosemary Harrup, Hock Choong Lai, M. Hasib Sidiqi, Nicole Wong Doo, David Routledge, Jay Hocking, Philip Campbell, Jessica Heenan, Noemi Horvath, Nicole Chien, William E. P. Renwick, Georgia McCaughan, Richard Eek, Douglas S. Lenton, Tricia Wright, Sher Gul Gazdar, Deepmala Mazumdar, Belinda Butcher, Peter Mollee, Hang Quach, Unknown

Open source

DOI
10.1111/bjh.70851
Published
2026-09-22
Container
British Journal of Haematology
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/bjh.70851,
  title = {Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3
                    <scp>ALLG MM23</scp>
                    (
                    <scp>SeaLAND</scp>
                    ) trial},
  author = {Matthew J. Rees and Masa Lasica and Anna Kalff and Michael Low and Rosemary Harrup and Hock Choong Lai and M. Hasib Sidiqi and Nicole Wong Doo and David Routledge and Jay Hocking and Philip Campbell and Jessica Heenan and Noemi Horvath and Nicole Chien and William E. P. Renwick and Georgia McCaughan and Richard Eek and Douglas S. Lenton and Tricia Wright and Sher Gul Gazdar and Deepmala Mazumdar and Belinda Butcher and Peter Mollee and Hang Quach and Unknown},
  year = {2026},
  journal = {British Journal of Haematology},
  doi = {10.1111/bjh.70851},
  url = {https://doi.org/10.1111/bjh.70851}
}

RIS

TY  - JOUR
TI  - Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3
                    <scp>ALLG MM23</scp>
                    (
                    <scp>SeaLAND</scp>
                    ) trial
AU  - Matthew J. Rees
AU  - Masa Lasica
AU  - Anna Kalff
AU  - Michael Low
AU  - Rosemary Harrup
AU  - Hock Choong Lai
AU  - M. Hasib Sidiqi
AU  - Nicole Wong Doo
AU  - David Routledge
AU  - Jay Hocking
AU  - Philip Campbell
AU  - Jessica Heenan
AU  - Noemi Horvath
AU  - Nicole Chien
AU  - William E. P. Renwick
AU  - Georgia McCaughan
AU  - Richard Eek
AU  - Douglas S. Lenton
AU  - Tricia Wright
AU  - Sher Gul Gazdar
AU  - Deepmala Mazumdar
AU  - Belinda Butcher
AU  - Peter Mollee
AU  - Hang Quach
AU  - Unknown
PY  - 2026
JO  - British Journal of Haematology
DO  - 10.1111/bjh.70851
UR  - https://doi.org/10.1111/bjh.70851
ER  - 

APA

Rees, M. J., Lasica, M., Kalff, A., Low, M., Harrup, R., Lai, H. C., Sidiqi, M. H., Doo, N. W., Routledge, D., Hocking, J., Campbell, P., Heenan, J., Horvath, N., Chien, N., Renwick, W. E. P., McCaughan, G., Eek, R., Lenton, D. S., Wright, T., Gazdar, S. G., Mazumdar, D., Butcher, B., Mollee, P., Quach, H., & Unknown (2026). Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 <scp>ALLG MM23</scp> ( <scp>SeaLAND</scp> ) trial. British Journal of Haematology. https://doi.org/10.1111/bjh.70851

Source records